SU1337098A1 - Method of treatment of duodenal peptic ulcer - Google Patents
Method of treatment of duodenal peptic ulcer Download PDFInfo
- Publication number
- SU1337098A1 SU1337098A1 SU833662633A SU3662633A SU1337098A1 SU 1337098 A1 SU1337098 A1 SU 1337098A1 SU 833662633 A SU833662633 A SU 833662633A SU 3662633 A SU3662633 A SU 3662633A SU 1337098 A1 SU1337098 A1 SU 1337098A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- treatment
- day
- aqueous solution
- patient
- peptic ulcer
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Дл сокращени сроков лечени нар ду с лечебным питанием, приемом антацидов, спазмалитиков, холиноли- тиков, седативных препаратов дополнительно назначают оксигенированный водный раствор с содержанием кислорода 0,8-1,2 мас.% с рН 7-8,5 по 6080 мл ежечасно в течение 14-17 дней. ITo shorten the treatment time, along with medical nutrition, antacids, spasmolytics, cholinolytics, and sedatives, an oxygenated aqueous solution with an oxygen content of 0.8-1.2 wt.% With a pH of 7-8.5 and 6080 ml every hour is additionally prescribed. within 14-17 days. I
Description
113113
Изобретение относитс к медицине, в частности к гастроэнтерологии.This invention relates to medicine, in particular to gastroenterology.
Целью изобретени вл етс сокращение сроков лечени .The aim of the invention is to reduce the duration of treatment.
Поставленна цель достигаетс тем что нар ду с лечебным питанием, приемом антацидов, спазмолитиков, холи- нолитиков, седативных препаратов, больным дополнительно назначают окси генированный водный раствор с содержанием кислорода 0,8-1,2% к массе с рН 7-8,5 по 60-80 мл ежечасно в течение 14-17 дней.This goal is achieved by the fact that, along with medical nutrition, taking antacids, antispasmodics, cholinolytics, sedatives, patients are additionally prescribed hydroxy aqueous solution with an oxygen content of 0.8-1.2% by weight with a pH of 7-8.5 60-80 ml hourly for 14-17 days.
Пример I, Больной К.В., 38 лет, диагноз: звенна болезнь, зва луковицы двенадцатиперстной кишки , рубцово- звенна деформаци лу- ковищ). При первичном эндоскопичес- .ком осмотре вы влена зва в луковице двенадцатиперстной кишки диаметром 0,5 0,4 см. Больному назначен курс лечени с применением диеты № 1, антацидов , спазмолитиков, холинолити Example I, Patient K.V., 38 years old, diagnosed with a link disease, anterior to the duodenal bulb, cicatricial link deformity of the onions). During the primary endoscopic examination, the heel of the duodenum with a diameter of 0.5 to 0.4 cm was detected. The patient was prescribed a course of treatment using the No. 1 diet, antacids, antispasmodics, cholinolitis
ков, седативных препаратов и оксиге- нированного водного раствора с содержанием кислорода 1,2% и рН 7,0 в дозе 660 мл/сут. по 60 мл ежечасно в течение дн . Болевой синдром купировалс на 6 день. Медикаментозна терапи отменена. Продолжалось лечение диетой № 1 и оксигенированным водным раствором. При контрольном эндоскопическом исследовании на 15 день вы влено полное рубцевание звы и значительное уменьшение поверхностных гастрических изменений. Больной вьтисан на 21 день в удовлетворительном состо нии., sedatives and an oxygenated aqueous solution with an oxygen content of 1.2% and a pH of 7.0 at a dose of 660 ml / day. 60 ml hourly for days. Pain syndrome was stopped on day 6. Drug therapy is canceled. Continued treatment with diet No. 1 and oxygenated aqueous solution. A final endoscopic examination on day 15 revealed complete cicatrization of ulcers and a significant reduction in superficial gastric changes. The patient was infected on day 21 in a satisfactory condition.
Пример 2. Больной З.Д., 44 года, диагноз: звенна болезнь, зва луковицы двенадцатиперстной кишки. При первичном эндоскопическом осмотре вы влена зва луковицы диаметром 0,6-0,4 см. Больному назначена обычна комплексна терапи и ок- сигенированна вода с содержанием кислорода 1,0% и рН 8,0 в дозе 700 мл/сут по 80 мл в течение дн . После купировани болевого синдрома на п тый день медикаментозна Терапи отменена. Продолжалось лечение диетой № 1 и оксигенированным водным раствором. При контрольном эндоскопическом исследовании на 16 день отмеВН1-1ИПИ Заказ 4070/7Example 2. Patient ZD, 44 years old, diagnosed with a link disease, of the duodenal ulcer. During the primary endoscopic examination, the bulbs of a diameter of 0.6-0.4 cm were detected. The patient was prescribed the usual complex therapy and oxygenated water with an oxygen content of 1.0% and a pH of 8.0 at a dose of 700 ml / day, 80 ml per day. for days After the relief of pain on the fifth day of the drug, therapies were canceled. Continued treatment with diet No. 1 and oxygenated aqueous solution. At the control endoscopic examination on the 16th day, mark VN1-1IPI Order 4070/7
Произв.-полигр. пр-тие, г. Ужгород, ул. Проектна , 4Random polygons pr-tie, Uzhgorod, st. Project, 4
00
чено рубцевание звы и исчезновение поверхностных воспалительных изменений слизистой. Больной выписан на 20 день в удовлетворительном сое- то нин.scarring of the ulcers and the disappearance of superficial inflammatory mucosal changes. The patient was discharged on the 20th day in a satisfactory connection.
Пример 3. Больной С.К., 32 года, диагноз: звенна болезнь, зва луковицы двенадцатиперстной кишки . При первичном эндоскопическом осмотре вы влена зва луковицы 0,7 0,4 см. Больному назначен курс лечени оксигенированным водным раствором с содержанием кислорода 0,8% иExample 3. Patient S.K., 32 years old, diagnosed with a link disease, of the duodenal ulcer. During the primary endoscopic examination, the bulb of 0.7 0.4 cm was detected. The patient was prescribed a course of treatment with an oxygenated aqueous solution with an oxygen content of 0.8% and
5 рН 8,5 в дозе 700 мл/сут {по 80 мл ежечасно в течение дн ), на фоне обычной комплексной терапии. На 6 день боли купировались и медикаментозна терапи отменена. Продолжа0 лось лечение оксигенированным водным раствором и диетой № 1. При контрольном эндоскопическом исследовании на 14 день вы влено уменьшение звенного дефекта до 0,1 см и уменьшение5 pH 8.5 at a dose of 700 ml / day {80 ml every hour per day), against the background of the usual complex therapy. On day 6, the pains were relieved and drug therapy was canceled. The treatment with oxygenated aqueous solution and diet No. 1 was continued. A control endoscopic examination on day 14 revealed a decrease in the ulcer defect to 0.1 cm and a decrease in
25 поверхностных гастрических изменений слизистой. Больной выписан на 23 день в удовлетворительном состо нии.25 superficial gastric mucosal changes. The patient was discharged on the 23rd day in a satisfactory condition.
Применение оксигенированного водного раствора с рП 7,0 вызывало уThe use of an oxygenated aqueous solution with RP 7.0 caused
30 больны непри тные ощущени в эпигас- тральной области и изжогу, а вода с рН 8,5 вызывала у больных непри тный привкус во рту и диспептические в- , лени .30 patients had unpleasant sensations in the epigastric region and heartburn, and water with a pH of 8.5 caused an unpleasant taste in the mouth and dyspeptic v-, laziness in patients.
У Таким образом, применение оксигенированного водного раствора при звенной болезни двенадцатиперстной приводит к уменьшению размеров звы, ускорению ее рубцевани и со40 кращению сроков лечени .Thus, the use of an oxygenated aqueous solution in duodenal ulcer leads to a reduction in the size of the ulcer, acceleration of its scarring and a reduction in the duration of treatment.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU833662633A SU1337098A1 (en) | 1983-11-15 | 1983-11-15 | Method of treatment of duodenal peptic ulcer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU833662633A SU1337098A1 (en) | 1983-11-15 | 1983-11-15 | Method of treatment of duodenal peptic ulcer |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1337098A1 true SU1337098A1 (en) | 1987-09-15 |
Family
ID=21089165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU833662633A SU1337098A1 (en) | 1983-11-15 | 1983-11-15 | Method of treatment of duodenal peptic ulcer |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU1337098A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011519861A (en) * | 2008-05-01 | 2011-07-14 | レバレジオ コーポレイション | Compositions and methods for treating gastrointestinal disorders |
US8349191B2 (en) | 1997-10-24 | 2013-01-08 | Revalesio Corporation | Diffuser/emulsifier for aquaculture applications |
US8410182B2 (en) | 2006-10-25 | 2013-04-02 | Revalesio Corporation | Mixing device |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US9198929B2 (en) | 2010-05-07 | 2015-12-01 | Revalesio Corporation | Compositions and methods for enhancing physiological performance and recovery time |
US9402803B2 (en) | 2006-10-25 | 2016-08-02 | Revalesio Corporation | Methods of wound care and treatment |
US9492404B2 (en) | 2010-08-12 | 2016-11-15 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
-
1983
- 1983-11-15 SU SU833662633A patent/SU1337098A1/en active
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349191B2 (en) | 1997-10-24 | 2013-01-08 | Revalesio Corporation | Diffuser/emulsifier for aquaculture applications |
US9034195B2 (en) | 1997-10-24 | 2015-05-19 | Revalesio Corporation | Diffuser/emulsifier for aquaculture applications |
US9004743B2 (en) | 2006-10-25 | 2015-04-14 | Revalesio Corporation | Mixing device for creating an output mixture by mixing a first material and a second material |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US9512398B2 (en) | 2006-10-25 | 2016-12-06 | Revalesio Corporation | Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles |
US8449172B2 (en) | 2006-10-25 | 2013-05-28 | Revalesio Corporation | Mixing device for creating an output mixture by mixing a first material and a second material |
US8470893B2 (en) | 2006-10-25 | 2013-06-25 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
US9511333B2 (en) | 2006-10-25 | 2016-12-06 | Revalesio Corporation | Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles |
US9402803B2 (en) | 2006-10-25 | 2016-08-02 | Revalesio Corporation | Methods of wound care and treatment |
US8962700B2 (en) | 2006-10-25 | 2015-02-24 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US8410182B2 (en) | 2006-10-25 | 2013-04-02 | Revalesio Corporation | Mixing device |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
EP2285347A4 (en) * | 2008-05-01 | 2011-09-21 | Revalesio Corp | Compositions and methods for treating digestive disorders |
JP2011519861A (en) * | 2008-05-01 | 2011-07-14 | レバレジオ コーポレイション | Compositions and methods for treating gastrointestinal disorders |
US9272000B2 (en) | 2009-04-27 | 2016-03-01 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US9011922B2 (en) | 2009-04-27 | 2015-04-21 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US9198929B2 (en) | 2010-05-07 | 2015-12-01 | Revalesio Corporation | Compositions and methods for enhancing physiological performance and recovery time |
US9492404B2 (en) | 2010-08-12 | 2016-11-15 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU1337098A1 (en) | Method of treatment of duodenal peptic ulcer | |
Jordan | Surgical management of postgastrectomy problems | |
EP0055118A1 (en) | Arthritis treatment | |
Lewis | Iron and Copper in the Treatment of Anemia in Children | |
Goel et al. | Dermatomyositis in childhood. Review of eight cases. | |
SU1105202A1 (en) | Method of treatment of gastric ulcer and duodenal ulcer | |
Robinson | Aspirin and the adrenal cortex | |
Kaplan | The allantoin treatment of ulcers | |
SU1162084A1 (en) | Method of treating patients after radiation lesion in acute period | |
Segal et al. | A polyamine formaldehyde resin IV. Clinical evaluation in the treatment of duodenal ulcer | |
Moses einhorn | The use of a new antispasmodic drug in gastro-enterology a preliminary report | |
RU2159631C1 (en) | Method for stopping hemorrhages from gastroduodenal peptic ulcers | |
RU2191579C2 (en) | Method of treatment of chronic gastritis and gastroduodenal ulcer associated with helicobacter pylori | |
De et al. | Penicillin in Treatment of Diphtheria | |
SU1725902A1 (en) | Method of children treatment with chronic tonsillitis | |
SU733684A1 (en) | Preparation "alanton" for treating erosive gastritis | |
RU2178299C2 (en) | Method to treat gastroduodenal ulcers | |
RU1780511C (en) | Method for treating peptic ulcer, chronic gastritis and colitis | |
YOUMANS et al. | GASTRIC TETANY: REPORT OF A CASE TREATED WITH AMMONIUM CHLORID | |
RU2004243C1 (en) | Method for treating psoriasis | |
RU2240119C1 (en) | Method for treatment of stomach and duodenum ulcerous disease | |
Ellis | Vagotomy in the surgical treatment of pyloric stenosis | |
RU2192867C2 (en) | Method for treating the cases of peptic gastric and duodenal ulcer disease | |
SU1641362A1 (en) | Method for treatment patients suffering from renal colic | |
SU858829A1 (en) | Method of treating virus hepatitis |